Related Experiment Video
Updated: May 12, 2026
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
A novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced
Tomohiko Shimo1, Yasushi Adachi, Sohsaku Yamanouchi
1Department of Pediatrics, Kansai Medical University, Osaka, Japan.
Background/Aims:
Minimal-change nephrotic syndrome (MCNS) is a kidney disease defined by selective proteinuria and hypoalbuminemia occurring in the absence of cellular glomerular infiltrates or immunoglobulin deposits. Recent observations suggest that nuclear factor κB (NF-κB) of podocyte is strongly associated with the development of proteinuria in MCNS. Dehydroxymethylepoxyquinomicin (DHMEQ) is a novel NF-κB inhibitor that potently inhibits DNA-binding activity of NF-κB, resulting in several therapeutic effects in various pathological conditions. We conducted this study to ask whether DHMEQ may ameliorate the nephrosis in mice induced by puromycin aminonucleoside (PAN), which is considered to be an animal model for MCNS.
Methods/Results:
Pretreatment with DHMEQ alleviated the proteinuria and reversed the serum abnormalities in mice nephrosis induced by 450 mg/kg of PAN. Increased serum interleukin-6 level in PAN-induced nephrosis was also completely suppressed by DHMEQ. Electron microscopic analyses of glo-meruli indicated that DHMEQ can inhibit the podocyte foot process effacement via blocking the translocation of podocyte NF-κB from cytoplasm to nucleus.
Conclusions:
These results suggest that DHMEQ can be a potential therapeutic agent for MCNS.
Insights
Dehydroxymethylepoxyquinomicin (DHMEQ) effectively treats minimal-change nephrotic syndrome (MCNS) in mice. This nuclear factor κB (NF-κB) inhibitor alleviates proteinuria and podocyte damage in a puromycin aminonucleoside (PAN)-induced nephrosis model.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Minimal-change nephrotic syndrome (MCNS) is characterized by proteinuria and hypoalbuminemia without glomerular immune deposits.
- Podocyte nuclear factor κB (NF-κB) activation is implicated in MCNS pathogenesis.
- Dehydroxymethylepoxyquinomicin (DHMEQ) is a novel NF-κB inhibitor with demonstrated therapeutic effects.
Purpose of the Study:
- To investigate the therapeutic potential of DHMEQ in a mouse model of MCNS.
- To determine if DHMEQ can ameliorate puromycin aminonucleoside (PAN)-induced nephrosis.
Main Methods:
- Mice were pretreated with DHMEQ before induction of nephrosis with PAN (450 mg/kg).
- Proteinuria, serum albumin, and creatinine levels were assessed.
- Interleukin-6 (IL-6) levels were measured.
- Electron microscopy evaluated podocyte foot process effacement and NF-κB translocation.
Main Results:
- DHMEQ pretreatment significantly alleviated proteinuria and corrected serum abnormalities in PAN-induced nephrosis.
- DHMEQ completely suppressed the elevated serum IL-6 levels observed in the nephrotic mice.
- Electron microscopy confirmed that DHMEQ inhibits podocyte foot process effacement by blocking NF-κB nuclear translocation.
Conclusions:
- DHMEQ demonstrates significant therapeutic effects in a mouse model of MCNS.
- DHMEQ represents a potential therapeutic agent for treating minimal-change nephrotic syndrome.
- Inhibition of NF-κB activation in podocytes is a viable strategy for MCNS treatment.
